Aligos Therapeutics, Inc. - Common stock (NQ:ALGS)

5.050 +0.060 (+1.20%)

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 16, 2026 Add to My Watchlist

Price and Volume

Volume	41,652
Open	5.010
Bid (Size)	4.800 (100)
Ask (Size)	5.300 (100)
Prev. Close	4.990
Today's Range	4.930 - 5.130
52wk Range	3.980 - 13.69
Shares Outstanding	42,940,089
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Discover the top movers in Wednesday's pre-market session. ↗

September 02, 2026

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 02, 2026

Gainers Can Fite Biopharma (AMEX:CANF) shares moved upwards by 20.4% to $3.96 during Wednesday's pre-market session. The company's market cap stands at $7.0 million. Aligos Therapeutics (NASDAQ:ALGS)...

Via Benzinga

Performance

YTD	-44.7%	-44.7%
1 Month	-23.2%	-23.2%
3 Month	+1.2%	+1.2%
6 Month	-30.8%	-30.8%
1 Year	-46.1%	-46.1%

More News

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

September 02, 2026

From Aligos Therapeutics

Via GlobeNewswire

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

August 12, 2026

From Aligos Therapeutics

Via GlobeNewswire

Aligos Therapeutics (NASDAQ:ALGS) Surges After Hours on Q1 Earnings Beat ↗

May 07, 2026

Via Chartmill

Aligos Therapeutics Inc (NASDAQ:ALGS) Reports Q4 Revenue Miss, Highlights 2026 Clinical Catalysts ↗

March 05, 2026

Via Chartmill

Keep an eye on the top gainers and losers in Monday's session. ↗

August 10, 2026

Via Chartmill

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

August 06, 2026

From Aligos Therapeutics

Via GlobeNewswire

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

July 30, 2026

From Aligos Therapeutics

Via GlobeNewswire

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

July 13, 2026

From Aligos Therapeutics

Via GlobeNewswire

The trading volume of these stocks is deviating from the norm in today's session. ↗

July 08, 2026

Via Chartmill

Monday's after hours session: top gainers and losers ↗

July 06, 2026

Via Chartmill

Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

July 06, 2026

From Aligos Therapeutics

Via GlobeNewswire

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

May 27, 2026

From Aligos Therapeutics

Via GlobeNewswire

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

May 13, 2026

From Aligos Therapeutics

Via GlobeNewswire

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

May 07, 2026

From Aligos Therapeutics

Via GlobeNewswire

Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026

April 30, 2026

From Aligos Therapeutics

Via GlobeNewswire

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 24, 2026

From Aligos Therapeutics

Via GlobeNewswire

Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

April 16, 2026

From Aligos Therapeutics

Via GlobeNewswire

Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation

April 14, 2026

From Aligos Therapeutics

Via GlobeNewswire

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results

March 05, 2026

From Aligos Therapeutics

Via GlobeNewswire

Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026

February 26, 2026

From Aligos Therapeutics

Via GlobeNewswire

Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)

February 23, 2026

From Aligos Therapeutics

Via GlobeNewswire

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 30, 2026

From Aligos Therapeutics

Via GlobeNewswire

Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates

January 21, 2026

From Aligos Therapeutics

Via GlobeNewswire

Frequently Asked Questions

Is Aligos Therapeutics, Inc. - Common stock publicly traded?

Yes, Aligos Therapeutics, Inc. - Common stock is publicly traded.

What exchange does Aligos Therapeutics, Inc. - Common stock trade on?

Aligos Therapeutics, Inc. - Common stock trades on the Nasdaq Stock Market

What is the ticker symbol for Aligos Therapeutics, Inc. - Common stock?

The ticker symbol for Aligos Therapeutics, Inc. - Common stock is ALGS on the Nasdaq Stock Market

What is the current price of Aligos Therapeutics, Inc. - Common stock?

The current price of Aligos Therapeutics, Inc. - Common stock is 5.050

When was Aligos Therapeutics, Inc. - Common stock last traded?

The last trade of Aligos Therapeutics, Inc. - Common stock was at 09/16/26 04:00 PM ET

What is the market capitalization of Aligos Therapeutics, Inc. - Common stock?

The market capitalization of Aligos Therapeutics, Inc. - Common stock is 216.85M

How many shares of Aligos Therapeutics, Inc. - Common stock are outstanding?

Aligos Therapeutics, Inc. - Common stock has 217M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.